Vivos Therapeutics (VVOS) Misses Q2 EPS by 16c

Vivos Therapeutics (NASDAQ: VVOS) reported Q2 EPS of ($0.55), $0.16 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.78 million.

For earnings history and earnings-related data on Vivos Therapeutics (VVOS) click here.

You May Also Be Interested In

• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
• South Korea's KOSPI Plunges 8%, Triggering Circuit Breaker
• Shopify To Bar Vapes As U.s. Authorities Crack Down On Illegal Industry - Reuters